Skip to main content

Press releases

28/12/25 - 18:48

Diasorin receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform (140.92 KB)
Products Molecular
Download

22/12/25 - 17:25

2026 Annual Corporate Events Calendar (117.34 KB)
Other
Download

22/12/25 - 17:18

Publication of documents for the Shareholders’ Meeting to be held on January 27, 2026 (144.42 KB)
Other
Download

22/12/25 - 14:36

The Board of Directors approved to submit to the Shareholders' Meeting the authorization for the purchase and cancellation of treasury shares for the purpose of shareholder remuneration. Ordinary and extraordinary shareholders' meeting convened. (125.84 KB)
Other
Download

24/11/25 - 11:10

Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
Products Molecular
Download

18/11/25 - 6:30

Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
Products Immunodiagnostic
Download

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
Products Molecular
Download

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
Products Immunodiagnostic
Download

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
Products Immunodiagnostic
Download

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
Products Molecular
Download

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
Products Molecular
Download

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)
Other
Download

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products
Download

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)
Other
Download

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)
Other
Download

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular
Download

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)
Other
Download

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)
Other
Download

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)
Other
Download

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)
Other
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it ), managed by Spafid Connect S.p.A., with registered office in Foro Bonaparte, 10, Milan, Italy.